Prevision Medicine wins second Future of Health Grant

Selected from more than 600 applications, Prevision Medicine is one of just two startups advancing to Level 3 of the Future of Health Grant programme. The 12-month programme will support the continued validation and deployment of PrevisionOne in clinical settings.

Moving from Level 2 to Level 3 marks an important next stage for Prevision Medicine. The 12-month validation programme will enable us to accelerate the deployment of our proprietary PrevisionOne platform with clinical partners, working alongside CSS and the Future of Health Grant team.

PrevisionOne is designed to support more personalized cancer treatment by testing a patient's own living cancer cells against more than 100 drugs and drug combinations. The platform can generate an actionable report within 72 hours, providing evidence to support treatment decisions.

Through the Level 3 programme, we will focus on generating real-world evidence as PrevisionOne is deployed in clinical settings. This work will help us further validate the platform and understand its impact in real-world healthcare environments. The Future of Health Grant has established a dedicated Pilot Factory to help startups evaluate digital health solutions in hospital environments, with a focus on measuring impact and generating evidence before wider implementation

Read the full announcement from the Future of Health Grant:
Future of Health Grant — Pilot Factory, 3 hospital pilots and 6 new start-ups

Read the coverage from StartupTicker:
StartupTicker — New advances power ahead the Future of Health Grant vision